Single B cell sorting is a new technology that isolates single antigen-specific plasma cells to retrieve Native™ antibodies with extremely high in vivo specificity and affinity. Creative Biolabs is happy to offer a comprehensive range of Native™ antibody discovery services based on our advanced B cell sorting platform.
Antibody technologies, including hybridoma technique, transgenic animal, phage display, and immortalized human B cell technology, have greatly promoted the development of therapeutic antibodies. A novel strategy, single B cell sorting technology (or single B cell cloning), has been pushed out in recent years for efficient and rapid Native™ antibody discovery. Based on directly cloning and expressing antibody genes from host B cells, single B cell sorting technology retrieves Native™ antibodies with the natural pairing of heavy and light chains and is featured with in vivo specificity and matured affinity. Usually, therapeutic antibody discovery by single B cell sorting technology is performed by the following:
Monoclonal antibody-based immunotherapy has achieved considerable success in tumor or cancer treatment over the past decades. The majority of the past approved therapeutic antibodies on the market are intended for tumor or cancer treatment. By targeting specific antigens overexpressed on tumor cells, blocking immune system inhibitors, conjugating to cytotoxic agents, or other effective mechanisms, these therapeutic antibodies have been proved to be more powerful and less toxic than traditional non-selective chemotherapy and radiotherapy.
Single B cell sorting technology has absolute advantages in antibody development for human cancer diagnosis and treatment. i) It isolates antibody-secreting B cells directly from tumor patients, which retrieves the Native™ antibodies with extremely high specificity and affinity against in vivo tumor environment. ii) It allows to select a large number of antibody candidates at once without additional engineering modifications, such as chimerization and humanization. iii) It greatly shortens the monoclonal antibody development timeline from 4 months to 1-2 months.
Fig.1 Antibodies produced by B cells can lead to the killing of tumor cells.1
With years of experience in antibody development for cancer treatment and state-of-the-art technology platforms, Creative Biolabs provides comprehensive Native™ antibody discovery services by single B cell technology for tumor diagnosis and treatment. If you are interested or have any questions, please don’t hesitate to contact us.
Reference
